指南与共识泌尿生殖与妇科肿瘤放疗放疗物理与技术

退伍军人事务部放射肿瘤学质量监测项目与美国放射肿瘤学会专家组的前列腺癌共识质量措施与剂量约束

Consensus Quality Measures and Dose Constraints for Prostate Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel.
指南 / 共识 · Pract Radiat Oncol · 2022-12-09

美国退伍军人事务部放射肿瘤学质量监测(VA ROQS)项目委托美国放射肿瘤学会组建前列腺癌专家组,于2021年2月至6月制定循证质量措施与绩效预期。共制定18项前列腺特异性措施(13项质量、2项理想、3项监测),并确定适用于常规、中度大分割和超大分割方案的剂量体积直方图(DVH)约束,以及18项CTCAE V5.0毒性术语。

要点

  • 共制定18项前列腺癌特异性措施:13项质量、2项理想、3项监测。
  • DVH指标分别针对常规、中度大分割和超大分割方案制定。
  • 随访评估优先选用18项CTCAE V5.0性、泌尿和胃肠道毒性术语。

核心结论

  • 这套措施与DVH约束可作为评估前列腺癌放射肿瘤学诊疗综合质量的工具。
  • 这些措施将用于退伍军人事务部及社区机构中退伍军人的持续质量监测与改进。
  • 这些措施也可应用于服务退伍军人之外的临床环境。

研究设计与样本

  • 美国退伍军人事务部国家放射肿瘤学项目设立VA ROQS项目,并与美国放射肿瘤学会签约,组建前列腺癌专家组(蓝丝带专家组)。
  • 专家组于2021年2月至6月制定质量、理想和监测措施,覆盖(1)初次会诊与检查、(2)模拟定位、治疗计划与实施、(3)随访。
  • 专家组选择用于根治性和前列腺切除术后放疗质量措施的剂量体积直方图(DVH)约束,并确定随访评估的最优CTCAE V5.0毒性术语。

主要发现

  • 共制定18项前列腺特异性措施,包括13项质量措施、2项理想措施和3项监测措施。
  • 确定了分别针对常规、中度大分割和超大分割方案的DVH指标。
  • 为每项措施制定了判定绩效的决策树。
  • 选择18项CTCAE V5.0术语,涵盖性、泌尿和胃肠道领域,作为随访期间最高优先评估项。

关键数值与推荐

  • 18项前列腺特异性措施:13项质量、2项理想、3项监测。
  • DVH指标按常规、中度大分割、超大分割方案分别制定。
  • 随访优先评估18项CTCAE V5.0性、泌尿和胃肠道毒性术语。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There are no agreed upon measures to comprehensively determine the quality of radiation oncology (RO) care delivered for prostate cancer. Consequently, it is difficult to assess the implementation of scientific advances and adherence to best practices in routine clinical practice. To address this need, the US Department of Veterans Affairs (VA) National Radiation Oncology Program established the VA Radiation Oncology Quality Surveillance (VA ROQS) Program to develop clinical quality measures to assess the quality of RO care delivered to Veterans with cancer. This article reports the prostate cancer consensus measures. METHODS AND MATERIALS: The VA ROQS Program contracted with the American Society for Radiation Oncology to commission a Blue Ribbon Panel of prostate cancer experts to develop a set of evidence-based measures and performance expectations. From February to June 2021, the panel developed quality, aspirational, and surveillance measures for (1) initial consultation and workup, (2) simulation, treatment planning, and delivery, and (3) follow-up. Dose-volume histogram (DVH) constraints to be used as quality measures for definitive and post-prostatectomy radiation therapy were selected. The panel also identified the optimal Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE V5.0), toxicity terms to assess in follow-up. RESULTS: Eighteen prostate-specific measures were developed (13 quality, 2 aspirational, and 3 surveillance). DVH metrics tailored to conventional, moderately hypofractionated, and ultrahypofractionated regimens were identified. Decision trees to determine performance for each measure were developed. Eighteen CTCAE V5.0 terms were selected in the sexual, urinary, and gastrointestinal domains as highest priority for assessment during follow-up. CONCLUSIONS: This set of measures and DVH constraints serves as a tool for assessing the comprehensive quality of RO care for prostate cancer. These measures will be used for ongoing quality surveillance and improvement among veterans receiving care across VA and community sites. These measures can also be applied to clinical settings outside of those serving veterans.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Solanki AA, Puckett LL, Kujundzic K, et al. Consensus Quality Measures and Dose Constraints for Prostate Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel. Pract Radiat Oncol. 2022. PMID: 36522277. doi:10.1016/j.prro.2022.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。